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Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid
neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations
affecting IDH2 and PIK3CA: a validation cohort
Aims: Solid papillary breast carcinoma resembling
the tall cell variant of papillary thyroid neoplasms
(BPTC), also known as solid papillary carcinoma
with reverse polarity, is a rare histological type of
breast cancer that resembles morphologically the
tall cell variant of papillary thyroid carcinoma.
BPTCs are characterised by IDH2 R172 hotspot
somatic mutations or mutually exclusive TET2
somatic mutations, concurrently with mutations
affecting PI3K pathway-related genes. We sought to
characterise their histology and investigate the fre-
quency of IDH2 and PIK3CA mutations in an inde-
pendent cohort of BPTCs, as well as in
conventional solid papillary carcinomas (SPCs).
Methods and results: Six BPTCs, not previously anal-
ysed molecularly, and 10 SPCs were reviewed cen-
trally. Tumour DNA was extracted from
microdissected histological sections and subjected to
Sanger sequencing of the IDH2 R172 hotspot locus
and exons 9 and 20 of PIK3CA. All six BPTCs
were characterised by solid, papillary and follicular
architecture with circumscribed, invasive tumour
nodules composed of epithelial cells with reverse
polarity. IDH2 mutations were identified in all six
BPTCs (three R172S, two R172T and one R172G),
four of which also harboured PIK3CA mutations
(two H1047R, one Q546K and one Q546R). By
contrast, all SPCs lacked IDH2 mutations, while
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one of 10 harboured a PIK3CA mutation
(H1047R).
Conclusion: We validated the presence of IDH2
R172 hotspot mutations and PIK3CA hotspot muta-
tions in 100% and 67% BPTCs tested, respectively,
and documented absence of IDH2 R172 mutations
in SPCs. These findings confirm the genotypical–
phenotypical correlation reported previously in
BPTC, which constitutes an entity distinct from
conventional SPC.
Keywords: breast cancer, IDH2, sanger sequencing
Introduction
Solid papillary breast carcinoma resembling the tall
cell variant of papillary thyroid neoplasms (BPTC),1
also known as breast tumour resembling the tall cell
variant of papillary thyroid carcinoma2,3 or solid pap-
illary carcinoma with reverse polarity,4 is a rare and
distinctive subtype of invasive breast cancer. First
recognised because of striking similarities with papil-
lary thyroid carcinomas (PTCs),3 including nuclear
diagnostic features (e.g. nuclear grooves and intranu-
clear pseudo-inclusions), BPTCs were catalogued fur-
ther under different terminologies, all of which are
synonyms. Despite histological similarities to papillary
thyroid neoplasms, clinical, immunohistochemical
and genetic data indicate that BPTCs are primary
breast tumours, given the lack of expression of thy-
roid-specific markers, including thyroid transcription
factor 1 (TTF1) and thyroglobulin,3,5,6 and somatic
genetic alterations typically found in PTCs, including
those affecting RET/PTC and BRAF3,6–8
Histologically, BPTCs are characterised by circum-
scribed tumour nodules lacking a peripheral layer of
myoepithelial cells growing in solid, papillary and/or
follicular architectural patterns.1,5,6 The term ‘reverse
polarity’ stems from the tumour cells harbouring
nuclei at the apical rather than the basal pole, thereby
creating the impression of reverse polarisation.4 The
polarisation of the cells, however, is preserved, with
expression of mucin 1 (MUC1) being found at the api-
cal luminal border.4 To date, 40 such tumours have
been reported.1–6 BPTCs are mainly of triple-negative
phenotype, with a third being weakly oestrogen recep-
tor (ER)-positive/human epidermal growth factor
receptor (HER2)-negative.1,3–6 Clinically, the majority
of BPTCs display an indolent biological behaviour with
an excellent prognosis; only two reported cases dis-
played axillary lymph node metastasis.1,3,5,6
We have demonstrated previously that BPTCs con-
stitute a discrete subtype of breast cancer under-
pinned by highly recurrent IDH2 R172 hotspot
somatic mutations or TET2 loss-of-function somatic
mutations, alongside PI3K pathway-related genes.4
As in leukaemias,9 IDH2 and TET2 mutations were
found to be mutually exclusive in BPTCs,4 function-
ing as alternative genetic drivers. In-vitro studies
demonstrated that expression of IDH2 mutations in
non-malignant breast epithelial cells results in a phe-
notype closely recapitulating that of BPTCs. While
Bhargava et al. recently described IDH2 R172 muta-
tions in two of three additional BPTCs,2 to the best of
our knowledge, IDH2 R172 mutations, which are
common in hematological malignancies and brain
tumours,10 have not been described in other breast
cancer subtypes.11–13 Here, we sought to characterise
the unique histology of BPTCs further and investigate
the frequency of IDH2 and PI3K catalytic subunit
alpha (PIK3CA) hotspot mutations in an independent
series of BPTCs, as well as in conventional solid papil-
lary carcinomas (SPCs) to define their potential
genetic relatedness.
Methods
C O H O R T
After obtaining approval by the Institutional Review
Boards and the local research ethics committees from
the authors’ institutions, six BPTCs, not previously
analysed molecularly, and 10 SPCs were retrieved,
reviewed centrally by three breast pathologists
(F.C.G., F.P. and E.B.) and anonymised prior to analy-
sis. Three cases were reported previously by Foschini
et al.1 (BPTC14, BPTC15, BPTC17).
M I C R O D I S S E C T I O N A N D D N A E X T R A C T I O N
Representative sections of formalin-fixed paraffin-
embedded BPTCs and SPCs were subjected to
microdissection to ensure > 80% tumour content, as
described previously,14,15 and DNA was extracted.
I M M U N O H I S T O C H E M I S T R Y ( I H C )
IHC data [cytokeratin (CK) 5/6, p63 and/or calponin]
from BPTC14, BPTC15 and BPTC17 was retrieved
from Foschini et al.1 Representative histological sec-
tions of BPTC18, BPTC19 and BPTC20 were analysed
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for CK5/6, p63 and/or smooth muscle myosin heavy
chain, as described previously16 (Supporting informa-
tion, Table S1). Positive and negative controls were
included in each slide run. ER, PR and HER2 IHC
data were retrieved from original pathology reports
for all cases.
S A N G E R S E Q U E N C I N G A N A L Y S I S
The IDH2 R172 hotspot residue and exons 9 and 20
of PIK3CA were investigated in the cohort of BPTCs
and SPCs by Sanger sequencing, as described previ-
ously (Supporting information, Table S2).15,17
Results
C L I N I C O P A T H O L O G I C A L C H A R A C T E R I S T I C S O F
B P T C
The six BPTCs occurred in female patients, with a
median age at diagnosis of 60 years (range = 58–
85 years). Tumour size ranged from 0.6 to 5.0 cm.
The histological features were consistent throughout
all cases (Figure 1, Supporting information, Fig-
ure S1). All BPTCs were multilobulated and charac-
terised by solid and papillary architecture, with
circumscribed and invasive tumour nodules composed
of epithelial cells displaying reverse polarity. Follicle-
like structures with colloid-like secretion were also
focally present. The nuclei displayed grade 2 pleomor-
phism, with occasional grooves and intranuclear
pseudo-inclusions. The six BPTCs were of histological
grade 1 and of triple-negative phenotype (Supporting
information, Table S3), expressed CK5/6 diffusely,
and lacked a myoepithelial cell layer (Figure 1I–L;
Supporting information, Table S3).
B P T C S H A R B O U R H I G H L Y R E C U R R E N T M U T A T I O N S
A F F E C T I N G I D H 2 A N D P I K 3 C A
Given that our previous study4 identified highly
recurrent mutations affecting the IDH2 R172 hot-
spot residue and PIK3CA hotspots in BPTCs, we
sought to define the frequencies of these mutations in
an independent set of BPTCs. Sanger sequencing
analysis revealed high mutation frequencies in both
genes (Figure 2). IDH2 R172 hotspot mutations were
found in 100% of BPTCs (six of six; three R172S, two
R172T and one R172G). PIK3CA hotspot mutations
were found in 67% of BPTCs (four of six; two
H1047R, one Q546K and one Q546R). These find-
ings are consistent with our previous study, which
identified IDH2 R172 hotspot and PIK3CA hotspot
mutations in 77 and 69% of BPTCs, respectively, and
concurrent IDH2 R172 hotspot and PIK3CA muta-
tions in 62% of BPTCs.4 In contrast, all conventional
SPCs lacked IDH2 R172 hotspot mutations (none of
10 versus six of six BPTCs, P < 0.001, Fisher’s exact
test), and 10% harboured a PIK3CA hotspot mutation
(H1047R; one of 10 versus four of six BPTCs,
P = 0.035, Fisher’s exact test; Supporting informa-
tion, Figure S2).
Discussion
Here we confirm that BPTC constitutes a rare histo-
logical type of breast cancer, with unique morpholog-
ical features and underpinned by highly recurrent
IDH2 R172 mutations alongside PIK3CA mutations.
Yet to be recognised as a special type of breast cancer
by the World Health Organisation (WHO) classifica-
tion of breast tumours,18 our previous4 and current
findings, together with those by Bhargava et al.2,
establish BPTC as a distinct histological type of inva-
sive breast carcinoma, driven by mutually exclusive
genetic alterations affecting the IDH2 R172 hotspot
residue or TET2, in conjunction with mutations in
PI3K pathway-related genes. Using in-vitro studies,
we have shown previously that expression of mutant
IDH2 in PIK3CA-mutant breast epithelial cells results
in the characteristic phenotype of BPTC.4 While PI3K
pathway-related gene mutations are common in
breast cancer,11–13 IDH2 mutations are vanishingly
rare or non-existent in other breast tumours.11–13
Indeed, the conventional SPCs analysed here lacked
IDH2 R172 mutations, consistent with their driver
role in the pathogenesis of BPTCs, and with the
notion that BPTC should not be perceived as a histo-
logical variant of SPC.
The mechanism by which IDH2 contributes to
tumorigenesis has yet to be understood fully. IDH2
mutations result in loss of catalytic activity and pro-
duction of a-ketoglutarate (a-KG) and gain of new
activity with production of the oncometabolite R-2-
hydroxylglutarate (R-2-HG).19–22 R-2-HG
competitively inhibits activity of a-KG-dependent
dioxygenases, altering genome-wide histones and
DNA methylation and resulting in abnormal epige-
netic regulation, cell differentiation and tumorigene-
sis.21,22 Importantly, IDH2-mutant BPTCs display a
hypermethylated profile and higher expression levels
of H3K27me3 compared to conventional forms of
invasive breast cancer.4 Importantly, however, the
mechanism by which IDH2 R172 hotspot mutations
or TET2 inactivating mutations alongside PI3K path-
way-related gene mutations result in phenotypic
© 2018 John Wiley & Sons Ltd, Histopathology, 73, 339–344.
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Figure 1. Morphological features of solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (BPTCs).
A,B, Low-power magnification of BPTC18 (A) and BPTC17 (B), displaying lobulated contours, without an infiltrative pattern (scale bar
1 mm). C, Solid and papillary architecture, with evident fibrovascular cores, often with perivascular hyalinised stroma, characterised all
BPTCs included in this study (BPTC14, scale bar 200 lm). D, Diffuse or focal follicle-like structures with colloid-like secretion were also
found in all cases (BPTC15, scale bar 200 lm). E,F, Reverse polarity, characterised by apical localisation of the nuclei and enhanced cyto-
plasmic granularity in the basal part, was also observed in all cases (E, BPTC15; F, BPTC19; scale bar 100 lm). G,H, All cases displayed
grade 2 nuclear atypia, with irregularities of the nuclear membrane, nuclear grooves (G, BPTC19, scale bar 50 lm) and intranuclear
pseudo-inclusions (H, BPTC19, scale bar 50 lm). In G and H, the highlighted nuclei with dashed lines are shown in the inset. I,J, BPTC19
diffusely expressed CK5/6 (I, scale bar 200 lm) and lacked a myoepithelial cell layer, as shown by immunohistochemistry for smooth muscle
myosin heavy chain (J, note a vessel wall as internal positive control, scale bar 200 lm). K,L, BPTC20 diffusely expressed CK5/6 (K, scale
bar 200 lm) and lacked a myoepithelial cell layer, as shown by immunohistochemistry for p63 (L, note the normal duct as internal positive
control, scale bar 200 lm).
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342 J R Lozada et al.
features similar to those found in BPTC remains to be
defined.
The identification of BPTC in clinical practice car-
ries important implications. BPTCs ought to be distin-
guished from conventional ER-positive SPCs, but still
recognised as a primary invasive neoplasm of the
breast requiring complete surgical excision. While its
infiltrative nature may be best ascertained with
immunohistochemistry,1 its immunoprofile with CK5/
6 expression and non-homogeneous cytomorphology
may be interpreted as evidence of a hyperplastic pro-
cess.2 Interestingly, a link between BPTC and infil-
trating epitheliosis, a complex sclerosing lesion with
overt, CK5/6-positive epithelial proliferation,16 has
been hypothesised due to similarities in immunopro-
file.2 While recurrent PIK3CA mutations have been
documented in infiltrating epitheliosis, IDH2 gene sta-
tus has yet to be investigated.16 Furthermore, BPTCs
ought to be distinguished from breast secretory carci-
nomas, which display a similar triple-negative pheno-
type and CK5/6 expression. Finally, although the
number of BPTCs with adequate follow-up is limited,
their outcome appears to be excellent despite the tri-
ple-negative or weakly ER-positive phenotype.1,2
Hence, patients with BPTCs are probably managed
adequately without adjuvant systemic therapy. Given
that IDH2 R172 mutations are probably pathog-
nomonic of BPTC in the context of breast carcinomas,
their identification may be used as a confirmatory
molecular finding.
This study has several limitations. First, given the
rarity of BPTC, the number of cases analysed is small.
Despite this, we validated the high frequency of IDH2
and PIK3CA mutations. Secondly, our results are lim-
ited to the selected IDH2 and PIK3CA hotspot resi-
dues, hence we cannot exclude the possibility of
additional concurrent genetic alterations in BPTCs,
such as a concurrent mutation in a PI3K pathway-
related gene in the PIK3CA wild-type cases. Finally,
further analyses of larger cohorts are warranted to
define the driver genetic alterations of BPTCs lacking
IDH2 or TET2 mutations.
Despite these limitations, our study has confirmed
the histological and genetic features that characterise
BPTCs, validating the high frequencies of mutations
affecting IDH2 and PIK3CA reported previously,4 and
demonstrating the genotypical–phenotypical correla-
tion that characterises this unique breast cancer sub-
type of favourable prognosis. As somatic mutations
affecting IDH2 R172 are vanishingly rare in other
breast tumours, they may be employed as ancillary
molecular markers in the diagnosis of BPTC.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Representative images of haematoxylin
and eosin-stained sections of each case. Cases are
reported in rows at 20x magnification (left), 100x
magnification (center) and 200 9 magnification
(right).
Figure S2. Sanger sequencing electropherograms of
the region encompassing the genomic position of the
IDH2 R172 hotspot residue (left) and the region
encompassing the genomic position of the PIK3CA
H1047 residue in the conventional solid papillary
carcinomas included in this study. The presence of a
mutation is highlighted by a black arrow.
Table S1. Immunohistochemistry staining methods.
Table S2. Primers used for Sanger sequencing analysis.
Table S3. Clinicopathologic and immunohistochemical
characteristics of six solid papillary breast carcinomas
resembling the tall cell variant of papillary thyroid neo-
plasms included in this study.
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